1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Alvotech’s Iceland Expansion Will Double Capacity

Extension Of Reykjavik Facility Expected To Be Complete By End Of 2022

 
• By Dave Wallace

As Alvotech advances towards launches around the world for its portfolio of biosimilars, the firm is ramping up capacity at its Reykjavik facility.

2x Bold Black Double
Alvotech’s expansion will double capacity at its Icelandic facility • Source: Shutterstock

Alvotech is laying the foundations for potential global launches of its biosimilars portfolio by doubling the size of its Reykjavik “high-tech center” at the University of Iceland’s Science Parks.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

More from Business